Abera Bioscience reports positive results from the final toxicological study on the company’s pneumococcal vaccine candidate
Abera Bioscience (“Abera” or “the Company”) has concluded the last toxicological study with Ab-01.12 and received the final report, demonstrating that the vaccine is well-tolerated,